ForecastedResearch announcementOpportunity RFA-OH-27-048

Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24)

Centers for Disease Control and Prevention - ERA · Department of Health and Human Services

At a glance

Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24) is a forecasted federal cooperative agreement opportunity from the Centers for Disease Control and Prevention - ERA (Department of Health and Human Services). The agency's forecast estimates an application due date of November 2, 2026; forecast dates can change. Individual awards are listed as $750K – $1.1M, with about 1 award expected and $5.5M in total estimated funding. The notice is unrestricted by applicant type, subject to any clarifications in the notice. Cost sharing is not required. It is funded under Assistance Listing 93.262 (Occupational Safety and Health Program).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Jul 22, 2026Forecast posted
Sep 2, 2026 (est.)Full notice expected
Nov 2, 2026 (est.)Application deadlinenext date
Aug 1, 2027 (est.)Est. award date

Posted: Jul 22, 2026
Est. close date: Nov 2, 2026
Est. award date: Aug 1, 2027
Award floor: $750,000
Award ceiling: $1,100,000
Est. total funding: $5,500,000
Expected awards: 1
Cost sharing: Not required
Funding instrument: Cooperative Agreement
Opportunity category: Discretionary
Fiscal year: FY2027

Who can apply

State governments
County governments
City or township governments
Special district governments
Independent school districts
Public colleges & universities
Federally recognized tribal governments
Public & Indian housing authorities
Native American tribal organizations
501(c)(3) nonprofits
Nonprofits without 501(c)(3) status
Private colleges & universities
For-profit organizations (not small businesses)
Small businesses
Others (see notice)
Unrestricted (any entity type)

Additional information on eligibility (from the notice)

Applicant institution must have an established registry and tissue bank with the capability of functioning as a national virtual registry and tissue bank for mesothelioma, one in which participating institutions will make available their independent stores of mesothelioma tissue for public access and use through a centralized Internet-based database or registry. This virtual registry and tissue bank must be able to provide a resource for investigators engaged in the research of mesothelioma, to include, but not limited to, biospecimens (blood, plasma, white blood cells, and normal and malignant mesothelioma tissues) together with demographic data such as age, sex, race, occupational history and other epidemiologic information, and clinical data (stage, treatment and survival information).Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are not allowed.

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The National Mesothelioma Virtual Bank (NMVB) was established in 2006 to serve as a resource for malignant mesothelioma research. This funding opportunity will advance biomedical research for malignant mesothelioma by adding more biospecimens together with demographic data and clinical data.

Examples of biospecimens include fresh frozen tumor and control tissues, paraffin embedded tissues, blood, DNA, RNA, and protein samples from mesothelioma patients. Demographic data includes age, sex, race, and occupational history. Clinical data includes stage, treatment, and survival information.

The virtual registry and tissue bank also serve as a virtual repository and offer a library of biospecimens and data that investigators can use and share, including genomic, transcriptomic, and proteomic data.

The NMVB can:

Help identify early signs of disease.
Support the development of biomarkers that show disease stage and prognosis.
Help develop new or improved treatment options.

The goal is to continue to expand the NMVB and improve its ability to be a resource for both biomedical researchers and the clinical science community focused on malignant mesothelioma research.

How to apply

0 of 8 done · progress saved in this browser

Read the full announcement (NOFO)Eligibility, evaluation criteria, page limits and required attachments are in the full notice on Grants.gov. Open ↗
Confirm eligibility and fitCheck your organization type above; no cost sharing is required.
Register (or renew) in SAM.gov and get a UEIFree. New registrations can take several weeks; registrations must be renewed every year. Open ↗
Set up Grants.gov accessCreate a Grants.gov account and make sure someone has the Authorized Organization Representative (AOR) role. Open ↗
Watch for the full noticeThe agency estimates posting it around September 2, 2026. Save this grant to track changes.
Prepare narrative, budget and attachmentsFollow the notice's format exactly — page limits and required forms are common reasons applications are rejected.
Ask the agency contact any questions earlyBridgette Garrett, PhD, Scientific Program Official · bgarrett@cdc.gov Open ↗
Submit before November 2, 2026Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. Application Due Dates: November 2, 2026 and March 2, 2027 Submit a few days early and keep your Grants.gov confirmation and validation emails.

Assistance Listing

What is an ALN?

93.262Occupational Safety and Health ProgramProgram →

Reported obligations under ALN 93.262

Historical data · not a prediction

FY24

$131M

FY25

$128M

FY26

$113M est.

Source: SAM.gov Assistance Listing 93.262. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Bridgette Garrett, PhD, Scientific Program Official
bgarrett@cdc.gov
770-488-5715

Quick answers

Is this opportunity open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around September 2, 2026. Forecast details and dates can change.

Who is eligible to apply for this opportunity?

The notice lists eligibility as unrestricted — open to any type of entity — subject to clarifications in the notice's additional eligibility information.

How much funding is available through this opportunity?

Per the notice, individual awards are listed as $750k – $1.1m, total estimated program funding is $5,500,000 and the agency expects to make about 1 awards.

How do I apply for this opportunity?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-OH-27-048), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

ForecastedResearchALN 93.262